报价延迟最少15分钟:2025/11/08 12:22 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
589.15 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
14.31/15.94
|
|
企业价值
16.81B
|
| 资产负债 |
|
每股账面净值
10.42
|
| 现金流量 |
|
现金流量率
0.04
|
| 损益表 |
|
收益
2.11B
|
|
每股收益
63.25
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/08 12:22 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services,including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |
